Health Care Equipment

Insulet

FactSet Survey: Insulet's Target Price Cut from $340 to $315

Insulet released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 761.7 M (forecast USD 730.1 M), actual EPS USD 1.3 (forecast USD 1.1618)

Insulet Reports Q1 2026 Financial Results Exceeding Expectations

Insulet Releases Clinical Evidence Report on Omnipod 5

UBS Increases Stake in Insulet

Insulet Releases 2025 Sustainable Development Report

FDA Issues Serious Recall of Insulet's Omnipod 5 Pods

Joel Isaacson & Co. LLC Significantly Increased Holdings in Insulet Corporation

Insulet to Release FY2026 Q1 Earnings on May 6, Pre-Market EST; Forecast Revenue USD 730.12 M, EPS USD 1.1618

Goldman Sachs Analyst Maintains Buy Rating on Insulet

RBC Capital Reiterates Buy Rating on Insulet with a Target Price of $380

Zevenbergen Capital Increases Holdings in Insulet Corporation by 113,083 Shares

Assenagon Increased Its Holdings in Insulet to 156,979 Shares

Insulet Recalls Certain Omnipod 5 Pods

Insulet Corporation Director Michael R. Minogue Acquires Company Shares

Insulet Corporation CEO Buys Company Stock

Insulet's stock price fell after analysts lowered their target prices

Insulet released FY2025 Q4 earnings on February 18 Pre-Market (EST), actual revenue USD 783.8 M (forecast USD 768.73 M), actual EPS USD 1.4405 (forecast USD 1.478)

Insulet released FY2025 annual earnings on February 18 Pre-Market EST, forecast revenue USD 2.692 B, forecast EPS USD 3.492, actual values not disclosed

Insulet Reports 31.2% Revenue Growth in FY2025 and Increases Stock Repurchase Authorization by $350 Million

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

PODD

Insulet Corp. (PODD) shares rose 1.39% to $154.61 on Tuesday, despite a broader market decline, with the S&P 500 and Dow Jones falling 0.67% and 0.65%, respectively. The stock remains 56.43% below its 52-week high of $354.88. Compared to competitors, Insulet underperformed as Eli Lilly, DexCom, and Johnson & Johnson saw gains of 3.37%, 2.86%, and 0.47%.

MarketWatch Automated

iShares US Medical Devices

SPDR S&P Health Equip

S&P 500

Dow Jones Industrial Average

Eli Lilly

DexCom

Johnson & Johnson

Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Insulet (PODD) reported strong Q1 results with revenue of $761.7 million and net income of $91.1 million, raising its 2026 revenue guidance. Despite this, its share price has dropped 24.8% in the past month and 47.4% year-to-date, indicating market reassessment of growth expectations. Analysts suggest the stock is undervalued, with a fair value of $326 compared to its current price of $148.84. The company is positioned for growth in the diabetes device market, but risks include potential device issues and competition. Investors are encouraged to evaluate the mixed signals in valuation models.

Simplywall

A Look At Insulet (PODD) Valuation After Strong Q1 Results And Raised Revenue Guidance

Shares of APA Corp. (APA) rose 1.06% to $37.09 on a mixed trading day, while the Dow Jones increased by 0.11% and the S&P 500 fell by 0.16%. This marks the second consecutive day of gains for APA Corp., although it remains 18.77% below its 52-week high of $45.66. Competitors EOG Resources, SLB Ltd., and Occidental Petroleum also saw gains, with trading volume at 6.1 million, below the 50-day average of 9.1 million.

EOG Resources

Occidental Petroleum

Factset Research

OCCIDENTAL PETROLEUM CORP C/W 03/08/27(OCCIDENTAL P)USD22

APA Corp. Stock Outperforms Competitors On Strong Trading Day

LABU

LABD

SBIO

Insulet Corp. (PODD) shares fell 3.89% to $154.16 on Friday, underperforming against competitors despite a positive market session. The S&P 500 rose 0.84%, while Insulet's stock remains 56.56% below its 52-week high of $354.88. Competitors Eli Lilly, DexCom, and Johnson & Johnson also saw declines, with trading volume at 1.7 million, surpassing the 50-day average of 1.2 million.

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Insulet Corp. Stock Underperforms Friday When Compared To Competitors

Insulet Corp. (PODD) shares rose 6.03% to $160.40 on a weak trading day for the market, with the S&P 500 down 0.38% and the Dow Jones down 0.63%. This increase ended a three-day losing streak, although the stock remains 54.80% below its 52-week high of $354.88. Insulet outperformed competitors like Eli Lilly, which fell 1.22%, and Johnson & Johnson, which dropped 0.94%. Trading volume reached 2.8 million, surpassing the 50-day average of 1.1 million.

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Oppenheimer has reduced its price target for Insulet (NASDAQ:PODD) from $300.00 to $210.00 while maintaining an "outperform" rating. This new target suggests a potential upside of 38.82% from the current stock price. Other firms have also adjusted their price targets, with a consensus rating of "Moderate Buy" and an average target of $309.71. Insulet's recent earnings report showed a 33.9% year-over-year revenue increase, with EPS of $1.42, exceeding estimates. The stock is currently trading at $151.28, down 9.7%.

Market Beat

Insulet (NASDAQ:PODD) Given New $210.00 Price Target at Oppenheimer

Insulet, a leader in the medtech industry, is enhancing its marketing efforts for the Omnipod wearable insulin patch. During its Q1 financials, CEO Ashley McEvoy highlighted the success of their recent promotion on the TV show "Scrubs," which raised awareness and engagement among diabetes patients. The episode featured a character managing Type 2 diabetes with the Omnipod, leading to increased interest and reactivation of prescriptions. Insulet plans to expand its peer-to-peer education program and continue focusing on market development.

Fiercepharma

Insulet details ‘Scrubs’ device promotion win

Insulet Corporation (NASDAQ:PODD) reached a new 52-week low of $152.25 after BTIG Research downgraded its price target from $320 to $260, maintaining a buy rating. Other analysts also lowered their targets, with an average price target of $324.38. Despite positive Q1 results and strong Omnipod demand, the stock has faced selling pressure, leading to a 9.8% decline. Eighteen analysts rate it as a buy, while five hold and one sell. Insulet's financial ratios indicate a solid position, with a market cap of $4.3 billion.

Insulet(PODD.US)